Our impact

Explore how our work translates scientific breakthroughs into real-world impact. Learn more about our success stories, our commitment to sustainable laboratory practices, and access our annual reports.

Our impact in numbers

14

new drugs to market

160+

new drugs into early-phase clinical trials

8 in 10

NHS cancer patients treated with cancer drugs receive a drug that Cancer Research UK helped develop

6m+

courses of treatment for cancers worldwide through drugs we helped to market

£600m+

reinvested in research from royalties and IP revenue

150+

active licences

£3bn+

raised by our start-up portfolio

79

start-ups formed

23

exits

Jonathan Kwok, co-founder of start-up Infinitopes, confidently smiling with his arms crossed

Infinitopes secures £12m seed financing

Success stories

Funding also supports the start of Phase 1/2a study for lead vaccine, ITOP1.

Read the story

Latest news

15 April 2025

First treatment for common bladder cancer recommended by NICE

14 April 2025

Support for new test to monitor people at risk of multiple myeloma

11 April 2025

Targeted breast cancer pill capivasertib (Truqap) approved for use by NHS

9 April 2025

Infinitopes granted Phase 1/2a clinical trial application approval to evaluate precision vaccine targeting early-stage oesophageal cancer

A man and a woman sat looking at a laptop

Discover how we're accelerating breakthroughs

Our annual reviews detail our research progress, commercial partnerships, start-ups and financial stewardship. We also champion responsible research through the UCL LEAF framework and report annually on our gender and ethnicity pay gap.

Read our reports